Sign in to view content

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies

David M. Brown, MD

Video
Published 2021

Related

Suprachoroidal CLS-TA Plus Aflibercept Compared With Aflibercept Monotherapy for DME: Results of a Phase 2 Trial
Michael S. Ip, MD
Annual Meeting Talks
2019
Episode 113: Journal Club, Macular Ischemia in RISE/RIDE, Wet Conversion in AMD, Micropulse for CSR
Jayanth Sridhar, MD
Member Podcasts
2018
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024

Category: Pharmacology

See more